Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express Inc (PETS), America's largest online pet pharmacy, provides this centralized hub for official corporate communications and market-moving developments. Access verified press releases, SEC filings, and strategic announcements from the nation's leading direct-to-consumer pet medication provider.
Investors and industry observers will find comprehensive coverage of financial results, regulatory updates, product innovations, and partnership agreements. Our curated news feed tracks material events impacting PETS' position in the $100B pet healthcare market, including prescription medication approvals and e-commerce platform enhancements.
Key updates include quarterly earnings disclosures, FDA compliance announcements, and distribution network expansions. All content is sourced directly from company filings and official statements to ensure regulatory compliance and factual accuracy.
Bookmark this page for real-time access to PETS' corporate communications, including 8-K filings detailing material events and 10-K annual reports. Check regularly for updates on the company's mission to deliver affordable pet healthcare through its innovative online pharmacy model.
PetMed Express (NASDAQ: PETS) reported its financial results for the fourth quarter and fiscal year ending March 31, 2024. Quarterly net sales rose 6.6% to $66.5 million, driven by the PetCareRx acquisition, but offset by a decline in legacy sales. However, the company posted a net loss of $5.0 million, or $0.25 per diluted share, primarily due to increased G&A and marketing expenses. Adjusted EBITDA fell to $0.5 million from $3.6 million in the prior year.
For the full fiscal year, net sales increased 9.5% to $281.1 million. The company recorded a net loss of $7.5 million, compared to a net income of $5.1 million the previous year, again due to higher G&A and marketing expenses. Annual Adjusted EBITDA declined to $8.2 million from $19.8 million. CEO Sandra Campos noted challenges in the macro environment and industry dynamics but emphasized efforts to improve systems and processes for better customer experience. Looking ahead, the company aims to drive growth, improve profitability, and enhance customer satisfaction.
PetMed Express, parent company of PetCareRx, announced several executive leadership changes to enhance growth and profitability. Caroline Conegliano joins as Chief Operating Officer (COO), leveraging two decades of experience in strategic transformation. Her role aims to optimize operations and customer satisfaction. Umesh Sripad is appointed Chief Digital and Technology Officer, focusing on digital-first strategies to boost customer experience and operational efficiency. Christine Chambers, CFO, will transition out by August 2024. The company is searching for a new CFO while Chambers assists with fiscal year-end reporting.
PetMed Express, parent company of PetCareRx, has appointed Carla Dodds as Chief Marketing Officer. Dodds brings extensive experience from major global companies like Walmart, MasterCard, and Penske Media. She will lead PetMeds’ integrated marketing strategy, encompassing brand and content, digital marketing, customer acquisition and retention, and market research. CEO Sandra Campos praised Dodds for her expertise in consumer behavior and innovative marketing campaigns. Dodds aims to leverage PetMeds’ unique platform to drive growth and enhance customer experience.
PetMed Express (Nasdaq: PETS) announced its upcoming earnings call to discuss the financial results for the fourth quarter and full fiscal year ended March 31, 2024. The call is scheduled for June 11, 2024, at 4:30 PM Eastern time. The financial results will be released in a press release prior to the call. PETS management will lead the conference, followed by a Q&A session. A telephonic replay will be available after the call until June 25, 2024.
PetMed Express, parent company of PetMeds and PetCareRx, has appointed Justin Mennen to its Board of Directors, effective June 3, 2024. Mennen brings over 25 years of technology experience, including roles at Rite Aid, CompuCom, Estée Lauder Companies, and Dell Technologies. His expertise encompasses digital commerce, enterprise technology, and cybersecurity. Chairman Leslie C. G. Campbell highlighted Mennen's vision for advancing digital initiatives, while CEO Sandra Campos emphasized his customer-centric philosophy and strategic acumen. Mennen expressed excitement about contributing to the company's growth during a transformative period.
PetMed Express, Inc. has appointed Sandra Campos as the new Chief Executive Officer and President. Campos, a retail E-commerce veteran, brings over 25 years of leadership experience to the role. The company aims to enhance shareholder value through a focus on customer experience, operational excellence, and digital marketing transformation.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
